Protection of CCRF-CEM human lymphoid cells from antifolates by retroviral gene transfer of variants of murine dihydrofolate reductase

Cancer Gene Therapy

Volumn 5, Issue 4, 1998, Pages 225-235

  Mareya, Shadreck M ^a   Sorrentino, Brian P ^a   Blakley, Raymond L ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Antifolate resistance; Gene therapy; Methotrexate; Myelosuppression; Recombinant enzymes; Trimetrexate

Indexed keywords

DIHYDROFOLATE REDUCTASE; FOLIC ACID ANTAGONIST; METHOTREXATE; RECOMBINANT PROTEIN; TRIMETREXATE;

ACUTE LYMPHOCYTIC LEUKEMIA; ANIMAL; ARTICLE; CELL CULTURE; COMPARATIVE STUDY; DRUG RESISTANCE; ENZYME STABILITY; ENZYMOLOGY; ESCHERICHIA COLI; GENE DOSAGE; GENE EXPRESSION REGULATION; GENE TRANSFER; GENETICS; HUMAN; METABOLISM; MOLECULAR CLONING; MOUSE; MUTATION; RETROVIRUS;

ANIMALS; CLONING, MOLECULAR; DRUG RESISTANCE, NEOPLASM; ENZYME STABILITY; ESCHERICHIA COLI; FOLIC ACID ANTAGONISTS; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TRANSFER TECHNIQUES; HUMANS; LEUKEMIA, LYMPHOCYTIC, ACUTE; METHOTREXATE; MICE; MUTATION; RECOMBINANT PROTEINS; RETROVIRIDAE; TETRAHYDROFOLATE DEHYDROGENASE; TRIMETREXATE; TUMOR CELLS, CULTURED;

EID: 0032113878     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Spencer HT, Sleep SEH, Rehg JE, Blakley RL, Sorrentino BP. A gene transfer strategy for making bone marrow cells resistant to trimetrexate. Blood 1996;87:2579-2587.
2. Morris JA, May C, Kim HS, et al. Comparative methotrexate resistance of transgenic mice expressing two distinct dihydrofolate reductase variants. Transgenics. 1996;2: 53-67.
3. Flasshove M, Banerjee D, Bertino JR, Moore MA. Increased resistance to methotrexate in human hematopoietic cells after gene transfer of the Ser31 DHFR mutant. Leukemia. 1995;9:S34-S37.
4. 34 mutant human dihydrofolate reductase into Chinese hamster ovary and mouse marrow progenitor cells confers methotrexate resistance. Gene. 1994;139:269-274.
5. Li MX, Banerjee D, Zhao SC, et al. Development of a retroviral construct containing a human mutated dihydrofolate reductase cDNA for hematopoietic stem cell transduction. Blood. 1994;83:3403-3408.
6. Hock RA, Miller AD. Retrovirus-mediated transfer and expression of drug resistant genes in human hematopoietic progenitor cells. Nature. 1986;320:275-277.
7. Kwok WW, Schuening F, Stead RB, Miller AD. Retroviral transfer of genes into canine hemopoietic progenitor cells in culture: a model for human gene therapy. Proc Natl Acad Sci USA. 1986;83:4552-4555.
8. May C, Gunther R, McIvor RS. Protection of mice from lethal doses of methotrexate by transplantation with transgenic marrow expressing drug-resistant dihydrofolate reductase activity. Blood. 1995;6:2439-2448.
9. Zhao SC, Li MX, Banerjee D, et al. Long-term protection of recipient mice from lethal doses of methotrexate by marrow infected with a double-copy vector retrovirus containing a mutant dihydrofolate reductase. Cancer Gene Ther. 1994;1:27-33.
10. Vinh DB-N, McIvor RS. Selective expression of methotrexate-resistant dihydrofolate reductase (DHFR) activity in mice transduced with DHFR retrovirus and administered methotrexate. J Pharmacol Exp Ther. 1993;267:989-996.
11. Corey CA, DeSilva AD, Holland CA, Williams, DA. Serial transplantation of methotrexate-resistant bone marrow: protection of murine recipients from drug toxicity by progeny of transduced cells. Blood. 1990;75:337-343.
12. Williams DA, Hsieh K, DeSilva A, Mulligan RC. Protection of bone marrow transplant recipients from lethal doses of methotrexate by the generation of methotrexate-resistant bone marrow. J Exp Med. 1987;166:210-218.
13. Allay JA, Spencer HT, Wilkinson SL, et al. In vivo selection of DHFR-modified murine hematopoietic progenitors by combined treatment with trimetrexate and thymidine transport inhibitors. Blood. 1996;88:645a.
14. Appleman JR, Beard WA, Delcamp TJ, Prendergast NJ, Freisheim JH, Blakley, RL. Atypical transient state kinetics of recombinant human dihydrofolate reductase produced by hysteretic behavior: comparison with dihydrofolate reductases from other sources. J Biol Chem. 1989;264: 2625-2633.
15. Appleman JR, Beard WA, Delcamp TJ, Prendergast NJ, Freisheim JH, Blakley, RL. Unusual transient- and steady-state kinetic behavior is predicted by the kinetic scheme operational for recombinant human dihydrofolate reductase. J Biol Chem. 1990;265:2740-2748.
16. Tsay J-T, Appleman JR, Beard WA, et al. Kinetic investigation of the functional role of phenylalanine-31 of recombinant human dihydrofolate reductase. Biochemistry. 1990;29:6428-6436.
17. Lewis WS, Cody V, Galitsky N, et al. Methotrexate-resistant variants of human dihydrofolate reductase with substitutions of leucine 22: kinetics, crystallography, and potential as selectable markers. J Biol Chem. 1995;270: 5057-5064.
18. Spencer HT, Sorrentino BP, Pui C-H, Chunduru SK, Sleep SE, Blakley RL. Mutations in the gene for human dihydrofolate reductase: an unlikely cause of clinical relapse in pediatric leukemia after therapy with methotrexate. Leukemia. 1996;10:439-446.
19. Patel M, Sleep SEH, Lewis WS, et al. Relative protection of human hematopoietic cells from methotrexate and trimetrexate by retroviral introduction of variants of human dihydrofolate reductase. Hum Gene Ther. 1997;8: 2069-2077.
20. 31 substitutions. J Biol Chem. 1994;269:9547-9555.
21. Stüber D, Bujard H, Hochuli E, et al. Enzymatic characterization of recombinant human dihydrofolate reductase produced in E. coli. In: Curtiss H-C, Ghisla S, Bau N, eds. Chemistry and Biology of Pteridines. New York, New York: Walter de Gruyter; 1986:839-842.
22. Stüber D, Matile H, Garotta H. System for high-level production in Escherichia coli and rapid purification of recombinant proteins: application to epitope mapping, preparation of antibodies, and structure-function analysis. Immunol Meth. 1990;4:121-125.
23. Ho SN, Hunt HD, Horton RM, Pullen JK, Pease LR. Site-directed mutagenesis by overlap extension using the polymerase chain reaction. Gene. 1989;77:51-59.
24. Chomczynski P. One-hour downward alkaline capillary transfer for blotting of DNA and RNA. Anal Biochem. 1992;201:134-139.
25. Cline MJ, Stang H, Mercola K, et al. Gene transfer in intact animals. Nature. 1980;284:422-425.
26. Isola LM, Gordon JW. Systemic resistance to methotrexate in transgenic mice carrying a mutant dihydrofolate reductase gene. Proc Natl Acad Sci USA. 1986;83:9621-9625.
27. Morris JA, McIvor RS. Saturation mutagenesis at dihydrofolate reductase codons 22 and 31. A variety of amino acid substitutions conferring methotrexate resistance. Biochem Pharmacol. 1994;47:1207-1220.
28. Thillet J, Adams JA, Benkovic SJ. The kinetic mechanism of wild-type and mutant mouse dihydrofolate reductases. Biochemistry. 1990;29:5195-5202.
29. Evenson DA, Adams A, McIvor RS, Wagner CR. Methotrexate resistance of mouse dihydrofolate reductase: effect of substitution of phcnylalanine-31 by serine or tryptophan. J Med Chem. 1996;39:1763-1766.
30. Li M, Hantzopoulos PA, Banerjee D, et al. Comparison of the expression of a mutant dihydrofolate reductase under control of different internal promoters in retroviral vectors. Hum Gene Ther. 1992;3:381-390.
31. Braun SE, McIvor RS, Davidson AS, et al. Retrovirally mediated gene transfer of Arg22 and Tyr22 forms of dihydrofolate reductase into the hematopoietic cell line K562: a comparison of methotrexate resistance. Cancer Gene Ther. 1997;4:26-32.
32. Stammers DK, Champness JN, Beddell CR, et al. The structure of mouse L1210 dihydrofolate reductase-drug complexes and the construction of a model of human enzyme. FEBS Lett. 1987;218:178-184.